Skip to main content
. 2024 Jan 31;12(1):e008232. doi: 10.1136/jitc-2023-008232

Table 3.

GI toxicity characteristics at time of infliximab failure

Variable (N=78)
Response to infliximab
 Nil 18 (23%)
 Partial (improvement, but not to ≤G1) 20 (26%)
 Initial (initial improvement to ≤G1, then relapse) 40 (51%)
Number of infliximab doses
 Median (range) 2 (1, 6)
Endoscopy post infliximab
 No 17 (22%)
 Yes 61 (78%)
Degree of inflammation endoscopically post infliximab
 Endoscopically normal 11 (18%)
 Rectum only 4 (7%)
 Sigmoid only 4 (7%)
 Left-sided (sigmoid+rectum) 11 (18%)
 Pancolitis 27 (45%)
 Upper gastrointestinal tract only 3 (4%)